Tag: QR-1123 Clinical Trials
QR-1123 (ProQR Therapeutics) Targeting P23H Mutation for Reduced Toxic Protein Production...
QR-1123 represents a groundbreaking advance in the fight against retinitis pigmentosa—a degenerative eye disease that can lead to blindness. Developed by ProQR Therapeutics, this...
